Cancer Clinical Trial
Official title:
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Verified date | May 2023 |
Source | Asana BioSciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
Status | Terminated |
Enrollment | 51 |
Est. completion date | July 2018 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Written informed consent obtained prior to any study-related procedure being performed; - Male or female subjects at least 18 years of age at the time of consent; - Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; - Recovered from the reversible effects of prior antineoplastic therapy (with the exception of alopecia and Grade 1 neuropathy). - Screening blood counts of the following: Absolute neutrophil count = 1000/µL, Platelets = 75,000/µL, Hemoglobin = 8 g/dL (with transfusion support); - Screening chemistry values of the following: Alanine aminotransferase (ALT) and aspartate transaminase (AST) = 3.0 × upper limit of the normal (ULN), total bilirubin = 1.5 × ULN, Creatinine = 1.5 × ULN; - At screening, life expectancy of at least 3 months; - Subject is willing and able to comply with all protocol required visits and assessments; - Male and female subjects of child-bearing potential must agree to use medically acceptable methods of birth control throughout the study and for thirty (30) days after the last dose of study medication. - (Part A only) Histologically or cytologically confirmed metastatic and/or advanced solid tumors or lymphomas for which no standard therapy exists, or who are not eligible for standard treatment. Subjects must have received at least one prior therapy for their malignancy; - (Part B only) Histologically confirmed DLBCL/MCL/FL/PTCL/MF/CLL on the basis of excisional lymph node or extranodal tissue biopsy; diagnosis of relapsed/refractory disease defined as 1) recurrence of disease after a Complete Response (CR), or 2) Partial Response (PR), Stable Disease (SD) at completion of treatment regimen preceding entry into study, subjects must not be candidates for standard therapy, subjects who have not received Stem Cell Translplant (SCT) must be ineligible to receive SCT. Exclusion Criteria - Have received prior chemotherapy regimens within 4 weeks of Day 1; - Have received prior treatment with monoclonal antibodies within 6 weeks of first dose of Day 1; - Have had major surgery within 30 days prior to the start of Day 1; - Received any investigational treatment within 4 weeks prior to the start of study medication; - Have had an infection requiring the use of parenteral antibiotics within 14 days prior to the start of Day 1; - Have known central nervous system metastasis or Central Nervous System lymphoma; - Is receiving high dose corticosteroids (>10 mg prednisone daily or equivalent); - Has known bleeding diathesis that would be a safety risk; - Has a history of other malignancy within the 3 years prior to screening, except adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ; - Has difficulty swallowing medications, or known history of malabsorption syndrome; - Has a serious concurrent medical condition, such as: congestive heart failure New York Heart Association (NYHA) class III or IV or uncontrolled hypertension at screening, 12-Lead electrocardiogram (ECG) abnormalities considered by the investigator to be clinically significant including myocardial infarction, angioplasty, or cardiac stent placement within the last 6 months, HIV infection, known Hepatitis B or C infection. Subjects at high risk for Hepatitis B or C infection should have serology testing to rule out infection, a medical condition requiring the therapeutic use of anticoagulants. - Known hypersensitivity to ASN002 or its excipients; - Prior participation, i.e., receipt of study medication, in this study; - Any condition that, in the opinion of the investigator, would impair the subject's ability to comply with study procedures; - Female subjects that are pregnant or lactating. - Part B only: Prior treatment with SYK or Janus Kinase (JAK) inhibitors, except MF subjects. |
Country | Name | City | State |
---|---|---|---|
Argentina | Hospital Universitario Austral | Buenos Aires | Derqui, Pilar |
Argentina | Instituto Alexander Fleming | Ciudad Autonoma de Buenos Aires | |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Winship Cancer Institute - Emory | Atlanta | Georgia |
United States | Gabrail Cancer Center | Canton | Ohio |
United States | Virginia Cancer Specialists | Fairfax | Virginia |
United States | START - Midwest | Grand Rapids | Michigan |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Oregon Health & Science University | Portland | Oregon |
United States | South Texas Accelerated Research Therapeutics | San Antonio | Texas |
United States | University of California, San Francisco | San Francisco | California |
United States | Arizona Oncology | Tempe | Arizona |
Lead Sponsor | Collaborator |
---|---|
Asana BioSciences |
United States, Argentina,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate | Due to the early termination of the study, data for efficacy endpoints were insufficient for the planned efficacy analyses. | First 29 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|